- Home
- VHUB vs IGC Comparison
VHUB vs IGC Comparison
Compare VHUB & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VHUB | IGC |
|---|---|---|
| Founded | 2000 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0M | 32.0M |
| IPO Year | 2025 | 2005 |
Fundamental Metrics
Financial Performance| Metric | VHUB | IGC |
|---|---|---|
| Price | $0.25 | $0.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 146.3K | ★ 519.9K |
| Earning Date | 11-14-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | N/A | ★ N/A |
| Revenue | $864,450.00 | ★ $1,271,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.25 | $0.24 |
| 52 Week High | $15.34 | $0.45 |
Technical Indicators
Market Signals| Indicator | VHUB | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 25.06 | 20.52 |
| Support Level | N/A | N/A |
| Resistance Level | $0.53 | $0.31 |
| Average True Range (ATR) | 0.05 | 0.02 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 9.64 | 56.78 |
Price Performance
Historical ComparisonAbout VHUB VenHub Global Inc. Common Stock
Venhub Global Inc is engaged in designing and building autonomous Smart Stores that operate 24/7 without on-site staff. Each store combines robotic automation, real-time inventory tracking, and mobile-based checkout to provide secure, convenient retail access, and is offered as an integrated retail solution to store operators.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.